One recent study looked at screening based on age and family history, while another looked at the effectiveness of fecal immunochemical testing with and without postpolypectomy surveillance colonoscopy.
One recent study found a link between depression and diarrhea and constipation, while another found that cognitive behavioral therapy may be an effective treatment for patients with refractory irritable bowel syndrome.
High-dose proton-pump inhibitors and aspirin appeared effective for chemoprevention in patients with Barrett's esophagus in one study, while another study found a positive association between human papillomavirus status and survival in patients with
This past month featured research on colorectal cancer prevention with both aspirin and diet, as well as a new clinical practice update from the American Gastroenterological Association on chemoprevention of colorectal neoplasia.
Over the past month, multiple studies found that kidney and liver transplantation using organs from deceased donors with hepatitis C virus (HCV) infection may be effective in HCV-negative recipients treated with a direct-acting antiviral regimen.
Recent studies looked at a nonendoscopic test for Barrett's esophagus in primary care, as well as screening for the condition before and after gastric bypass procedures.
An open-label randomized trial looked at long-term albumin administration in patients with decompensated disease, and another evaluated the use of IV albumin in hospitalized patients with cirrhosis and hyponatremia at admission.
One recent study compared postpolypectomy surveillance with colonoscopy versus fecal immunochemical testing, while another assessed the rate of postpolypectomy complications in patients prescribed antithrombotic agents.
Irritable bowel syndrome (IBS) was the focus of two recent studies this month, which analyzed patients with symptoms of diarrhea-predominant IBS and IBS after infectious enteritis.
Research in the past month found that infliximab blunts the body's immune response to COVID-19 infection, that both infliximab and adalimumab are effective in long-term treatment of outpatients with inflammatory bowel disease (IBD), and that